dc.contributor.author | Çoban, Arzu | |
dc.contributor.author | Matur, Zeliha | |
dc.contributor.author | Hanagasi, Hasmet A. | |
dc.contributor.author | Parman, Yeşim | |
dc.date.accessioned | 2019-09-02T06:32:44Z | |
dc.date.available | 2019-09-02T06:32:44Z | |
dc.date.issued | 2010 | en_US |
dc.identifier.issn | 0362-5664 | |
dc.identifier.issn | 1537-162X | |
dc.identifier.uri | https://doi.org/10.1097/WNF.0b013e3181d479e0 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12462/6105 | |
dc.description | Çoban, Arzu (Balikesir Author) | en_US |
dc.description.abstract | Therapeutic use of botulinum toxin type A (BT/A) is well known, effective, and safe. Iatrogenic botulism that presents with generalized weakness, dysphagia, and respiratory distress is a rare but significant complication in BT/A treatment. In this study, we report 4 patients who developed iatrogenic botulism after receiving therapeutic doses of BT/A for spasticity and blepharospasm. One patient was placed in intensive care unit, but consequently, every patient recovered fully. The cause of BT/A as an adverse effect is most likely hematological spread of the toxin. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.isversionof | 10.1097/WNF.0b013e3181d479e0 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Iatrogenic Botulism | en_US |
dc.subject | Botulinum Toxin A | en_US |
dc.subject | Spasticity | en_US |
dc.subject | Blepharospasm | en_US |
dc.title | Iatrogenic botulism after botulinum toxin type a injections | en_US |
dc.type | other | en_US |
dc.relation.journal | Clinical Neuropharmacology | en_US |
dc.contributor.department | Tıp Fakültesi | en_US |
dc.contributor.authorID | 0000-0002-3895-0410 | en_US |
dc.identifier.volume | 33 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 158 | en_US |
dc.identifier.endpage | 160 | en_US |
dc.relation.publicationcategory | Diğer | en_US |